Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers

Modern Pathology

Volumn 11, Issue 9, 1998, Pages 855-863

  Kelly, Thomas ^a   Kechelava, Sofia ^a   Rozypal, Tricia L ^a   West, Kenneth W ^a   Korourian, Soheila ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Extracellular matrix; Invadopodia; Invasion; Metastasis; Seprase; Serine integral membrane protease

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEINASE; SEPRASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CELL LABELING; CHICK EMBRYO; CLINICAL ARTICLE; ENZYME ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MEMBRANE BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; GELATINASES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MEMBRANE PROTEINS; MIDDLE AGED; SERINE ENDOPEPTIDASES; TUMOR MARKERS, BIOLOGICAL;

EID: 0031663242     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-8.
2. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
3. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann Rev Cell Dev Biol 1993;9:541-73.
4. Chen W-T, Lee C-C, Goldstein L, Bernier S, Liu CHL, Lin C-Y, et al. Membrane proteases as potential diagnostic and therapeutic targets for breast malignancy. Breast Cancer Res Treat 1994;31:217-26.
5. Coopman PJ, Thomas DM, Gehlsen KR, Mueller SC. Integrin α3β1 participates in the phagocytosis of extracellular matrix molecules by human breast cancer cells. Mol Biol Cell 1996; 7:1789-804.
6. Kelly T, Mueller SC, Yeh Y, Chen W-T. Invadopodia promote proteolysis of a wide variety of extracellular matrix proteins. J Cell Physiol 1994;158:299-308.
7. Monsky WL, Lin C-Y, Aoyama A, Kelly T, Akiyama SK, Mueller SC, et al. A potential marker protease of invasiveness, seprase, is localized to invadopodia of human malignant melanoma cells. Cancer Res 1994;54:5702-10.
8. Nakahara H, Nomizu M, Akiyama SK, Yamada Y, Yeh Y, Chen W-T. A mechanism for regulation of melanoma invasion. J Biol Chem 1996;271:27221-4.
9. Aoyama A, Chen W-T. A 170-kDa membrane-bound protease is associated with the expression of invasiveness by human malignant melanoma cells. Proc Natl Acad Sci U S A 1990;87:8296-300.
10. Pineiro-Sanchez M, Goldstein LA, Dodt J, Howard L, Yeh Y, Chen W-T. Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J Biol Chem 1997;272:7595-601.
11. Bordier C. Phase separation of integral membrane proteins in Triton X-114 solution. J Biol Chem 1981;256:1604-7.
12. Pinkus G, O'Connor EM, Etheridge CL, Corson JM. Optimal immunoreactivity of keratin proteins in formalin-fixed, paraffin-embedded tissue requires preliminary trypsinization: an immunoperoxidase study of various tumors using polyclonal and monoclonal antibodies. J Histochem Cytochem 1985;33:465-73.
13. Hsu SM, Raine L, Fanger H. A comparative study of peroxidase-antiperoxidase and avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 1981;75:734-8.
14. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359-77.
15. Nakahara H, Howard L, Thompson EW, Sato H, Seiki M, Yeh Y, et al. Transmembrane/cytoplasmic domain-mediated membrane-type 1 matrix metalloprotease docking to invadopodia is required for cell invasion. Proc Natl Acad Sci U S A 1997;94:7959-64.
16. Kelly T, Yan Y, Osborne RL, Athota AB, Rozypal TL, Colclasure JC, et al. Proteolysis of extracellular matrix by invadopodia facilitates human breast cancer cell invasion and is mediated by matrix metalloproteinases. Clin Exp Metastasis 1998;16 (in press).
17. Goldberg GI, Eisen AZ. Extracellular matrix metalloproteinase in tumor invasion and metastasis. In: Lippman ME, Dickson RB, editors. Regulatory mechanisms in breast cancer. Boston, MA: Kluwer; 1990. p. 421-40.
18. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, et al. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993;67:1126-31.
19. Brown PD, Bloxidge RE, Anderson E, Howell A. Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis 1993;11:183-9.
20. Emonard HP, Remacle AG, Noel AC, Grimaud JA, Stetler SW, Foidart JM. Tumor cell surface-associated binding site for the M(r) 72,000 type IV collagenase. Cancer Res 1992;52: 5845-8.
21. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990;348:699-704.
22. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S. Plasminogen activator system in human breast cancer. Int J Cancer 1992;50:345-8.
23. Schmitt M, Goretzki L, Janicke F, Calvete J, Eulitz M, Kobayashi H, et al. Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. Biomed Biochim Acta 1991;50:731-41.
24. Reilly D, Andreasen PA, Duffy MJ. Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay. Blood Coagul Fibrinolysis 1991;2:47-50.
25. Lah TT, Kokalj KM, Drobnic KM, Babnik J, Golouh R, Vrhovec I, et al. Cystatins and cathepsins in breast carcinoma. Biol Chem 1992;373:595-604.
26. Gabrijelcic D, Svetic B, Spaic D, Skrk J, Budihna M, Dolenc I, et al. Cathepsins B, H, and L in human breast carcinoma. Eur J Clin Chem Clin Biochem 1992;30:69-74.
27. Dengler R, Lah T, Gabrijelcic D, Turk V, Fritz H, Emmerich B. Detection of cathepsin B in tumor cytosol and urine of breast cancer patients. Biomed Biochim Acta 1991;50:555-60.
28. Lah TT, Kokalj KM, Strukelj B, Pungercar J, Barlic MD, Drobnic KM, et al. Stefins and lysosomal cathepsins B, L, and D in human breast carcinoma. Int J Cancer 1992;50:36-44.
29. Rochefort HA. Cathepsin D in breast cancer. Breast Cancer Res Treat 1990;16:3-13.
30. Ueno H, Nakamura H, Inoue M, Imai K, Noguchi M, Sato H, et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997;57:2055-60.
31. Yu M, Sato H, Seiki M, Thompson EW. Complex regulation of membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation by concanavalin A in MDA-MB-231 human breast cancer cells. Cancer Res 1995; 55:3272-7.
32. Pulyaeva H, Washington D, Bueno J, Sato H, Seiki M, Azumi N, et al. MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells. Clin Exp Metastasis 1997;15: 111-20.
33. Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, et al. Molecular cloning of fibroblast activation protein α, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A 1994;91:5657-61.
34. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995; 55:1856-62.
35. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 1995;6:967-74.
36. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996;56:2815-22.